Clinical Trials Arena· GlobalData Healthcare·· 3 小时前AI 评分42
IDWeek 2026：meropenem-pilabactam 成功靶向关键优先病原体
IDWeek 2026: meropenem-pilabactam successfully targets critical priority pathogens
AI 导读
IDWeek 2026 数据显示，meropenem 与 pilabactam 联用可拓宽 meropenem 对多重耐药病原体的抗菌效力。该组合针对的是关键优先病原体。
来源：Clinical Trials Arena · clinicaltrialsarena.com